Abstract:

Objective：To observe the clinic efficacy and safety of used recombinant human brain natriuretie peptide（rh-BNP）on patients with acute decompensated heart failure.Methods：48 patients who suffered from acute decompensated heart failure patients were divided into rh-BNP group（n=22）and control group（n=26）.The rh-BNP group received rh-BNP made by China and traditional heart failure treatment; the control group was treated with traditional heart failure treatment.The changes of the clinical efficacy, left ventricular ejection fraction（LVEF）and brain natriuretie peptide test parameters were observed.Results：After 7 days treatment, clinical efficacy improvements were more significant in rh-BNP group compared control group（81.7% vs 61.6，P<0.05）.LVEF were improved in rh-BNP group compared with control group（（51±6）% vs（46±5）%，P<0.01）.and BNP level were decreased obviously in
rh-BNP group than control group（（498±209）pg/ml vs（642±318）pg/ml，P<0.01），and there had positive relation in BNP decrease and LVEF increased（P<0.05）.Conclusion：The use of rh-BNP is efficient and safe for acute decompensated heart failure patient.And BNP test can provide a dog marker for diagnosis and prognostic.

Key words: recombinant human brain natriuretic peptide, acute heart failure, brain natriuretie peptide, ejection fraction